Edgewise Therapeutics’ Post

Exciting developments in weight loss treatment! 🚀 Dr. Ian Neeland from University Hospitals Harrington Heart & Vascular Institute is leading groundbreaking research on GLP-1 agonists like semaglutide, liraglutide, and tirzepatide. Read how his work aims to deepen our understanding of these meds and shape clinical guidelines for heart and vascular care: https://lnkd.in/eDQt-4Fe

IFESS 2024: a glimpse back from the workshop "Translational electrical stimulation for use in neurorehabilitation - applied clinical evidence" The scientific and clinical evidence presented was perfectly aligned with the objective of transferring it into clinical practice. The theoretical part, led by the workshop's leading experts, Winfried Mayr, Thomas Schick and Ines Bersch, was concluded with a practical session. This enabled the participants to gain hands-on experience with multichannel stimulation and transcutaneous spinal cord stimulation.

In my opinion, this is a super important topic that you can't avoid when it comes to neurological or #SCI rehabilitation. I'm very excited to see how this topic will develop in the future🚀 #translationalelectricalstimulation #tSCS

One more day to submit your short talk and poster abstracts #EASD2024!

A day to remember how important research is for science and, even more so, for people’s lives. Advocating for more clinical trials and safe data that can improve people’s lives and bring cures to rare diseases. #duchennemusculardystrophy #beckermusculardystrophy

The abstract deadline for the Tumor Microenvironment and Cell Stress Conference 2024 is approaching. Here are some tips to help you organize your research and submit a compelling abstract: 🔹Start early: Begin organizing your data and drafting your abstract as soon as possible to avoid last-minute rush. 🔹Focus on key findings: Highlight the most significant results and discoveries from your research. 🔹Clear and concise: Keep your abstract to the point, focusing on the main objectives, methods, results, and conclusions. 🔹Proofread: Double-check your abstract for any grammatical errors or typos before submission. 🔹Seek feedback: Consider sharing your abstract with colleagues or mentors for constructive feedback and suggestions. 🔹Visit EasyConferences Abstract Submission System before the deadline. Seek help from their dedicated staff at info@easyconferences.eu #TMCS2024 #AbstractDeadline Costas Koumenis Albert Koong Triantafyllos Stylianopoulos Erato Stylianou Markidou Maria Tsiarli

Sometimes the pursuit of science is personal and inspiring.

Attending the AD/PD conference in Lisbon this week? Our chief medical officer, Gabriel Vargas, MD, PhD, will give an oral presentation of our impressive Phase 2a data in Alzheimer’s and Parkinson’s disease patients this Sat March 9 at 17:25 UTC. CuraSen’s combination adrenergic activator, CST-2032/CST-107, achieved statistically and clinically important effects across several cognitive domains, such as memory, attention, executive function, facial recognition and impulse control — areas known to be impacted by adrenergic function. We plan to initiate longer studies with CST-2032/CST-107 in AD/PD patients with MCI later this year. https://lnkd.in/ghSxqppm #AD#PD#MCI

Great insights from Veeral Sheth, MD, MBA, FASRS, FACS on the exciting potential of neuroregeneration for restoring vision with promising advancements in ongoing clinical studies. View the full video here 👉 https://lnkd.in/ggQGQGZY

Did you know May is Hepatitis Awareness Month and May 19 is World Hepatitis Testing Day? In recognition, we're highlighting updates and unmet needs in the management of #HepatitisB, with a Special Report featuring Chari Cohen, DrPH, MPH, of the Hepatitis B Foundation, Nancy Reau, MD, of RUSH University Medical Center, and Andrew Talal, MD, of Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo. Check out the first segment of the 6-part discussion below and use the link for the remainder of the conversation! https://lnkd.in/eXaFrPMe #HepatitisAwarenessMonth